Skip to main content

Table 1 Baseline characteristics of the study population (n = 11)

From: Morbidity and mortality of nonagenarians undergoing CoreValve implantation

Variable

Clinical parameters

Male, n (%)

4 (36.4)

Age (yrs)

92.6 ± 1.3

BMI (kg/m2)

28.6 ± 3.0

Hypertension, n (%)

9 (81.8)

Dyslipidemia (%)

9 (81.8)

Smoker, n (%)

3 (27.3)

Diabetes mellitus, n (%)

7 (63.6)

Renal insufficiency (creatinine level > 1.5mg/dl), n (%)

6 (54.5)

Chronic hemodyalisis, n (%)

2 (18.2)

Chronic obstructive pulmonary disease, n (%)

2 (18.2)

New York Heart Association functional class (grade)

3.2 ± 0.8

Logistic EuroSCORE (%)

32.0 ± 9.5

STS score (%)

25.3 ± 9.7

Dyspnoe, n (%)

11 (100)

Angina, n (%)

4 (36.4)

Syncope, n (%)

4 (36.4)

Cardiac decompensation, n (%)

5 (45.5)

Pulmonal artery systolic pressure (mmHg)

40.8 ± 18.7

Porcelain aorta, n (%)

0 (0)

Ischemic heart disease, n (%)

8 (72.7)

Previous percutaneous coronary intervention, n (%)

6 (54.5)

Previous coronary artery bypass graft surgery, n (%)

4 (36.4)

Peripheral vessel disease, n (%)

2 (18.2)

Previous stroke, n (%)

2 (18.2)

Laboratory findings

Hemoglobin (mg/dl)

7.8 ± 1.2

Hematokrit (%)

37.7 ± 4.8

Creatinine (μmol/l)

183.9 ± 223.6

MDRD

48.2 ± 24.6

Medication

Aspirin

7 (63.6)

ACE-Inhibitor

7 (63.6)

ARB

2 (18.2)

Beta-Blocking agent

8 (72.7)

Ca-chanel blocker

3 (27.3)

Antiarythmic agent

0 (0)

Statin

7 (63.6)